Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.63 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3521585 | 0.99 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3IDO1AGXT | |
| Hydrochloric Acid SCHEMBL3521582 | 0.99 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3IDO1AGXT | |
| SCHEMBL12012208 | 0.83 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3IDO1TACR1 | |
| Hydrochloric Acid SCHEMBL3524592 | 0.82 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3IDO1TACR1 | |
| Hydrochloric Acid SCHEMBL3524589 | 0.82 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3IDO1TACR1 | |
| SCHEMBL18616424 | 0.81 | ALDH1A1 (0.61) | IDO1AGXTALDH1A1EEDTACR1 | |
| SCHEMBL3789138 | 0.80 | SLC6A2 (0.58) | SLC6A4SLC6A2SLC6A3IDO1AGXT | |
| SCHEMBL3789134 | 0.80 | SLC6A2 (0.58) | SLC6A4SLC6A2SLC6A3IDO1AGXT | |
| SCHEMBL12012233 | 0.80 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23072237 | 0.80 | ALDH1A1 (0.60) | SLC6A4IDO1AGXTNAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | SLC6A4 416/4885SLC6A2 333/4885SLC6A3 499/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | SLC6A4 416/4885SLC6A2 333/4885SLC6A3 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.